2019 AZBio Fast Lane Award Honoree - OncoMyx Therapeutics

SUMMARY

The National Cancer Institute (NCI) estimates that there will be over 600,000 deaths from cancer in 2019.  That is roughly two percent of the U.S population.  The majority of these deaths will be caused by cancers that form into solid tumors.
OncoMyx, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have emerged as a safe and effective immuno-oncology complement. The company’s MYXV platform is poised to be a best-in-class oncolytic virus approach, and the top oncolytic virus team has assembled around MYXV to create important new therapeutic options for cancer patients. OncoMyx is currently being launched in Phoenix to test next-generation viruses in human clinical trials against a variety of human cancers.
https://www.azbio.org/oncomyx-therapeutics-inc-to-be-honored-with-an-azbio-fast-lane-award